TAXUS

Appeals Court Affirms That J&J Stents Infringe Boston Scientific Patent; Claims Against TAXUS Liberte Dismissed

NATICK, Mass., March 31 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) announced today that the Court of Appeals for the Federal Circuit issued a decision in the Company's stent litigation with Johnson and Johnson (J&J). The Court of Appeals upheld the District C...

SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents

Coronary artery bypass grafting (CABG) should remain the "standard of care" for patients with complex coronary artery disease, concludes the SYNTAX study, published in the New England Journal of Medicine (online February 18, 2009, Print edition March 5). The SYNTAX study, led jointly by Patri...

ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent

WASHINGTON, DC OCTOBER 22, 2007 Late-breaking results from the ENDEAVOR IV trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting stent met the trials primary endpoint, demonstrating a similar overall sa...

FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent

...t received CE Mark approval in 2007. "The taxus Liberte Long Stent offers physicians and patients ...yland. "In the ATLAS Long Lesion Trial, the 38 mm taxus Liberte Stent significantly reduced myocardial inf...d to the TAXUS((R)) Express((R)) Stent, making the taxus Liberte Long Stent an attractive option for interv...

Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials

...e the excellent clinical outcomes, with XIENCE V demonstrating an 88 percent reduction in cardiac death and a 57 percent reduction in MACE compared to taxus at three years in the SPIRIT II trial. At two years in the SPIRIT III trial, XIENCE V demonstrated a 45 percent reduction in the risk of MACE compared...

SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System

...percutaneous coronary intervention (PCI) using the taxus Stent to coronary artery bypass graft (CABG) surge...ients with left main disease (149 treated with the taxus Stent and 114 treated with CABG). It is designed ...nd non-distal. For those patients receiving a taxus Stent, the patency rate for the treated lesion was...

Boston Scientific Announces Schedule for EuroPCR 2009

... Thursday, May 21 taxus Woman Study: Gender Differences in Outcomes. Rob...clinical outcomes in 2,271 patients who received a taxus paclitaxel-eluting stent in the taxus I, II, IV, V and ATLAS studies, during an abstract...

Drug-Coated Stents Better at Keeping Arteries Open

... given stents after heart attacks, comparing outcomes for the 2,257 who got taxus stents, coated with the drug paclitaxel, with the 749 who received bare-met...s, the American trial was supported by Boston Scientific, which markets the taxus stent. Again, the rate of re-stenosis was significantly lower in the gro...

Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009

...percent, while the observed cardiac death rate for taxus Express2/Liberte more than tripled to 4.2 percent ...MACE) rate of 6.4 percent, while the MACE rate for taxus Express2/Liberte increased 40 percent to 14.9 perc...bosis (1.0 percent). The stent thrombosis rate for taxus Express2/Liberte at three years increased to 2.9 p...

'Green chemistry' could ease manufacture, boost usefulness of cancer drug

...l byproducts." Walker, an assistant professor of chemistry, biochemistry and molecular biology, studies enzymes that assemble the Taxol molecule in taxus plants. "This process is like painting from a palette," Walker said. "We can add select colors to the palette from which the enzyme chooses, so the mo...

TAXUS in Medical Technology

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent

New coronary stent features thin struts designed for more uniform drug delivery NATICK, Mass., and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced comprehensive data from the TAXUS ATLAS clinical program,...

TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials

NATICK, Mass. and CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from a pooled analysis of patients from its TAXUS IV and TAXUS V randomized clinical trials. The analysis compared the safety and efficacy of the TAXUS(R) Expr...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

One-year Data Demonstrate Continued Safety, Consistently Positive Clinical Results with XIENCE V WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial demonstrated continued positive, statistically signifi...

Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent

MIAMI LAKES, Fla., Sept. 4 /PRNewswire/ -- In an extensive analysis of clinical trials known as a meta-analysis, the CYPHER(R) Sirolimus-eluting Coronary Stent was associated with significantly lower risks of blood clots and the need for reintervention compared to the Taxus Stent out to 30 mon...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

While no significant differences were found, results showed CYPHER(R) Stent had lower mortality and heart attack rates VIENNA, Austria, Sept. 4 /PRNewswire/ -- A subgroup analysis of diabetic patient data from a two-year randomized controlled trial comparing the CYPHER(R) Sirolimus...

Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent

TAXUS(R) Stent shows no additional very late stent thrombosis NATICK, Mass. and VIENNA, Austria, Sept. 4 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced five-year and final results from its TAXUS II clinical trial, demonstrating continued long-term sa...

SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems

SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year NATICK, Mass. and BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the results of additional data from the SPIRIT FIRST, II and III Clinical Trials, reaffirming pri...

Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the publication of an article in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS clinical trial, which evaluates the Company's second-generation TAXUS(R) Liberte(TM)(1) paclitaxel-elut...

New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent, Implantation of Multiple Stents and Small Vessel Size To Be Independent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX News Network/ -- An analysis of data from the Western Denmark ...

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

...tent in high risk of restenosis patients. However, the thrombosis rate for taxus treated patients increased from one to two years from 4.2% to 5.3%, with an...0.0%). Myocardial infarctions (MI) increased from years one to two in the taxus patients to 6.3%, while the MI rate in the Genous patients remained steady ...

TAXUS in Medical Products

TAXUS Express2 Monorail Paclitaxel-Eluting Coronary Stent System

Description:... The taxus Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in...
Company:Boston Scientific Corporation

TAXUS Express2 Over-the-wire Paclitaxel-Eluting Coronary Stent System

Description:... The taxus Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in...
Company:Boston Scientific Corporation

TAXUS in Medical Dictionary

Yew

...lichiana) ... yew (Amentotaxus sp.) Plum- yew (Cephalotaxus ... taxus baccata is a conifer native to western, central and southern Europe, northw...rees becoming known, it may be... (Click to enlarge) yew common yew taxus baccata (Wendy Smith) yew n. Any of several poisonous evergreen trees or ...

TAXUS in Biological Technology

Prix Galien USA Announces 2009 Final Candidates

... Therapeutics, REMODULIN(R) Wyeth, Prevnar (R) Best Medical Device: Abbott Vascular, XIENCE (R) Boston Scientific, taxus (R) DCA Design, Lantus(R)( )SoloSTAR(R) GlaxoSmithKline, Veramyst(R)( )Mistpro(TM) Veridex, CellSearch(R) CTC Test "No...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...y stent systems incorporating the drug paclitaxel. taxus stents have been evaluated by the industry's most ...oval registries. To date, approximately 11 million taxus stents have been implanted globally, making them t...ry stents. Royalty revenue derived from sales of taxus stents by BSC for the second quarter of 2009 decre...

Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent

...onth. It received CE Mark approval in 2007. "The taxus Liberte Long Stent offers physicians and patients ...ryland. "In the ATLAS Long Lesion Trial, the 38 mm taxus Liberte Stent significantly reduced myocardial inf...pared to the TAXUS(R) Express(R) Stent, making the taxus Liberte Long Stent an attractive option for interv...

Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system

.... The Company plans to begin a full U.S. launch of taxus Liberte Atom next month. "The rapid adoption of the taxus Express Atom Stent has confirmed the need for this...on Adventist Hospital, Takoma Park, Maryland. "The taxus Liberte Atom Stent provides clear design and deliv...

FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System

... The Company plans to begin a full U.S. launch of taxus Liberte Atom next month. "The rapid adoption of the taxus Express Atom Stent has confirmed the need for this...n Adventist Hospital, Takoma Park, Maryland. "The taxus Liberte Atom Stent provides clear design and deliv...

SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System

...percutaneous coronary intervention (PCI) using the taxus Stent to coronary artery bypass graft (CABG) surge...ients with left main disease (149 treated with the taxus Stent and 114 treated with CABG). It is designed t...l and non-distal. For those patients receiving a taxus Stent, the patency rate for the treated lesion was...

Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent

...nary Stent System in select markets worldwide. The taxus Element Stent features a new platinum chromium all...eration drug-eluting stent (DES) technology. The taxus Element Stent is built on the advanced platinum ch...orted that it anticipates CE Mark approval for the taxus Element Stent in the fourth quarter of this year. ...

Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009

...mers at levels observed in prior periods. New taxus Regulatory Submissions, Clinical Data. In February...dules for pre-market approval ("PMA") for both its taxus Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System and its taxus Liberte Long(TM) Paclitaxel-Eluting Coronary Stent...

OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients

... with the Genous treated patient group compared with patients receiving the taxus drug eluting stent, but there were no stent thrombosis events at any time p...with only one month of dual antiplatelet therapy (DAPT). In the 95 patient taxus cohort, the stent thrombosis rate was 4.2%, including late stent thromboses...

Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008

...07. FDA Approval Received by our Partner BSC for taxus Liberte(R) and taxus Express Atom(TM) Stents. On October 10, 2008, we a...n ("FDA") to market and sell the second generation taxus Liberte(R) Paclitaxel-Eluting Coronary Stent Syste...